A number of other equities analysts have also commented on the stock. Raymond James lowered shares of Medexus Pharmaceuticals from an outperform rating to a market perform rating and cut their price objective for the company from C$4.50 to C$2.00 in a research report on Tuesday. Stifel Nicolaus dropped their target price on shares of Medexus Pharmaceuticals from C$14.25 to C$11.00 in a research report on Wednesday, August 10th.
Medexus Pharmaceuticals Price Performance
MDP stock opened at C$7.75 on Thursday. The firm has a 50 day moving average of C$7.75 and a 200-day moving average of C$7.75. The company has a current ratio of 1.19, a quick ratio of 0.74 and a debt-to-equity ratio of 1,174.36. Medexus Pharmaceuticals has a 12 month low of C$2.80 and a 12 month high of C$9.75. The firm has a market capitalization of C$148.54 million and a P/E ratio of -4.28.
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older.
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.